{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:27:48Z","timestamp":1756312068123,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Hereditary transthyretin cardiac amyloidosis (hATTR-CA) is a rare autosomal dominantly inherited disease caused by mutations in the transthyretin (TTR) gene. TTR mutations often cause the instability of transthyretin, production of misfolded proteins, and ultimately excessive deposition of insoluble amyloid fibrils in the myocardium, thereby leading to cardiac dysfunction. Herein, we report a novel transthyretin D39Y mutation in a Chinese family. We characterized the kinetic and thermodynamic stabilities of D39Y mutant TTR, revealing that TTR D39Y mutant was less stable than WT TTR and more stable than amyloidogenic mutation TTR L55P. Meanwhile, the only FDA approved drug Tafamidis showed satisfactory inhibitory effect toward ATTR amyloid formation and strong binding affinity in test tube revealed by isothermal titration calorimetry. Finally, we measured the well-folded tetrameric TTR concentration in patient\u2019s and his descents\u2019 blood serum using a previously reported UPLC-based assay. Notably, the tetramer concentrations gradually increased from symptomatic D39Y gene carrier father, to asymptomatic D39Y gene carrier daughter, and further to wild type daughter, suggesting the decrease in functional tetrameric TTR concentration may serve as an indicator for disease age of onset in D39Y gene carriers. The study described a Chinese family with hATTR-CA due to the TTR variant D39Y with its destabilizing effect in both kinetic and thermodynamic stabilities.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1091183","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T06:09:57Z","timestamp":1674713397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of a novel transthyretin mutation D39Y in a cardiac amyloidosis patient and its biochemical characterizations"],"prefix":"10.3389","volume":"10","author":[{"given":"Qunchao","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey).","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/circulationaha.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0065-3233(08)60321-6","article-title":"Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.","volume":"50","author":"Kelly","year":"1997","journal-title":"Adv Protein Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/acs.biochem.1c00073","article-title":"Thermodynamic stability and aggregation kinetics of EF helix and ef loop variants of transthyretin.","volume":"60","author":"Ferguson","year":"2021","journal-title":"Biochemistry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression.","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid."},{"key":"B7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines.","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid."},{"key":"B8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.abb.2013.03.005","article-title":"The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells.","volume":"535","author":"Zhang","year":"2013","journal-title":"Arch Biochem Biophys."},{"key":"B9","doi-asserted-by":"publisher","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity.","volume":"99","author":"Hammarstr\u00f6m","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/13506129.2011.560215","article-title":"Thermodynamic stability and denaturation kinetics of a benign natural transthyretin mutant identified in a danish kindred.","volume":"18","author":"Groenning","year":"2011","journal-title":"Amyloid."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange.","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian cardiovascular society\/Canadian heart failure society joint position statement on the evaluation and management of patients with cardiac amyloidosis.","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice.","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1021\/bi800636q","article-title":"Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.","volume":"47","author":"Hurshman Babbes","year":"2008","journal-title":"Biochemistry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease.","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13527","DOI":"10.1021\/bi00041a032","article-title":"Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.","volume":"34","author":"McCutchen","year":"1995","journal-title":"Biochemistry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/13506129.2013.797890","article-title":"Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.","volume":"20","author":"Ihse","year":"2013","journal-title":"Amyloid."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma.","volume":"98","author":"Purkey","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B22","first-page":"1575","article-title":"Prealbumin: a marker for nutritional evaluation.","volume":"65","author":"Beck","year":"2002","journal-title":"Am Fam Phys."},{"key":"B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.","volume":"421","author":"Johnson","year":"2012","journal-title":"J Mol Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/13506129.2010.483118","article-title":"Serum transthyretin levels in Swedish TTR V30M carriers.","volume":"17","author":"Buxbaum","year":"2010","journal-title":"Amyloid."},{"key":"B25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13506120802525285","article-title":"Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity.","volume":"15","author":"Buxbaum","year":"2008","journal-title":"Amyloid."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin.","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail."},{"key":"B27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamacardio.2020.5969","article-title":"Association of low plasma transthyretin concentration with risk of heart failure in the general population.","volume":"6","author":"Greve","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid."},{"key":"B29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy.","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy.","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis.","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS).","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or hispanic\/latino ancestry.","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1007\/s12035-017-0694-0","article-title":"A missense variant p.Ala117Ser in the transthyretin gene of a han Chinese family with familial amyloid polyneuropathy.","volume":"55","author":"Chen","year":"2018","journal-title":"Mol Neurobiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2011.02.005","article-title":"Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family.","volume":"304","author":"Liu","year":"2011","journal-title":"J Neurol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/eye.2013.217","article-title":"Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation.","volume":"28","author":"Liu","year":"2014","journal-title":"Eye."},{"key":"B37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jns.2007.10.011","article-title":"Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression.","volume":"267","author":"Liu","year":"2008","journal-title":"J Neurol Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrd3675","article-title":"Tafamidis.","volume":"11","author":"Said","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study.","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1091183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T06:10:01Z","timestamp":1674713401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1091183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2023.1091183"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1091183","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"1091183"}}